CMV retinitis: a clinical management update.
Blanchet
K D
KD
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000465:Algorithms; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077404:Cidofovir; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003587:Cytomegalovirus / Q000187:drug effects; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000517:prevention & control; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004343:Drug Implants; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D017245:Foscarnet / Q000008:administration & dosage* / Q000009:adverse effects; D015774:Ganciclovir / Q000008:administration & dosage*; D006801:Humans; D007267:Injections / Q000379:methods; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010358:Patient Participation; D014822:Vitreous Body
D000998:Antiviral Agents; D004343:Drug Implants; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D015774:Ganciclovir